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Abstract
Vascular effects of estradiol are being investigated because there are controversies among clinical and experimental studies.
DNA microarrays were used to investigate global gene expression patterns in cultured human umbilical vein endothelial
cells (HUVEC) exposed to 1 nmol/L estradiol for 24 hours. When compared to control, 187 genes were identified as
differentially expressed with 1.9-fold change threshold. Supervised principal component analysis and hierarchical cluster
analysis revealed the differences between control and estradiol-treated samples. Physiological concentrations of estradiol
are sufficient to elicit significant changes in HUVEC gene expression. Notch signaling, actin cytoskeleton signaling, pentose
phosphate pathway, axonal guidance signaling and integrin signaling were the top-five canonical pathways significantly
regulated by estrogen. A total of 26 regulatory networks were identified as estrogen responsive. Microarray data were
confirmed by quantitative RT-PCR in cardiovascular meaning genes; cyclooxigenase (COX)1, dimethylarginine
dimethylaminohydrolase (DDAH)2, phospholipase A2 group IV (PLA2G4) B, and 7-dehydrocholesterol reductase were up-
regulated by estradiol in a dose-dependent and estrogen receptor-dependent way, whereas COX2, DDAH1 and PLA2G4A
remained unaltered. Moreover, estradiol-induced COX1 gene expression resulted in increased COX1 protein content and
enhanced prostacyclin production. DDAH2 protein content was also increased, which in turn decreased asymmetric
dimethylarginine concentration and increased NO release. All stimulated effects of estradiol on gene and protein expression
were estrogen receptor-dependent, since were abolished in the presence of the estrogen receptor antagonist ICI 182780.
This study identifies new vascular mechanisms of action by which estradiol may contribute to a wide range of biological
processes.
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Introduction
The incidence of coronary heart disease is greater in men than
in premenopausal women of the same age, but increases in
frequency after menopause, an effect that has been attributed, at
least in part, to estrogens [1]. Estrogens have been used as
contraceptive agents or as principal constituents of hormone
replacement therapy formulations in postmenopausal women,
17b-estradiol being the most widely used molecule. The
cardiovascular protective effect detected in a considerable number
of observational clinical studies [2] has not been confirmed by
more recent randomized placebo-controlled trials designed to
study the effects of hormonal therapy in either secondary [3,4] or
primary [5] prevention. It should be stated that the clinical trials of
estrogen therapy for the treatment of cardiovascular disease are
largely flawed (e.g., hormone replacement therapy started too late
in menopause). Moreover, a number of studies have demonstrated
a favorable profile for estrogens in both experimental animal as
well as in vitro models [6].
Endothelium is crucial to the modulation of vessel tone and to
the control of platelet adhesion and aggregation, two key factors in
the initiation and development of atherosclerosis [7]. Endotheli-
um, including human umbilical vein endothelial cells (HUVEC),
expresses both types of estrogen receptors (ER), a and b, and the
actions of estrogens on endothelium have been exhaustively
studied [8]. Moreover, clinical and experimental data support the
consideration of endothelium as a target for sexual hormones [9].
Estradiol effects on partial gene expression in endothelial cells have
frequently been studied, but there is a lack about its effects on the
whole gene expression profile.
Microarrays are high-throughput genomic tools that allow the
comparison of global expression changes in thousands of genes
between different experimental conditions in cell/tissue analysis,
and they have been widely adopted for analyzing the global gene
expression profiles in vivo and in vitro [10]. Recent studies have
demonstrated the ability of this technology for investigating
molecular pathophysiological mechanisms involved in a variety
of human diseases. For instance, microarray technology has been
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gene expression in different cardiovascular diseases [11], athero-
sclerosis [12] and experimental stroke in rats [13].
Microarray technology offers the possibility of exploring a large
number of candidate genes which are modified by estrogens. The
present study aims to explore gene expression modification, mainly
focused on candidate genes that may regulate the vascular effects
of estrogens, in cultured human endothelial cells exposed to
physiological concentrations of estradiol by using microarrays,
thus providing new information to the available body of
knowledge about the influence of estradiol on the vascular wall.
Materials and Methods
Ethics Statement
This investigation conforms to the principles outlined in the
Declaration of Helsinki, was approved by the Ethical Committee
of Clinical Research of the University Clinical Hospital of
Valencia, and written informed consent was obtained from all
donors.
Cell Culture and Experimental Design
Primary HUVEC were isolated, grown, and identified as
described earlier [14] in human endothelial cell-specific Medium
EBM-2 (Lonza, Basel, Switzerland), supplemented with EGM-2
(Lonza), in an incubator at 37uC with 5% CO2.
Cells from passages 4 to 6 were seeded onto 25 cm
2 flasks for
mRNA isolation. When cells were at 75% of confluence, culture
medium was exchanged for a phenol red–free Medium 199
(GIBCO, Invitrogen, Barcelona, Spain) supplemented with 20%
charcoal/dextran-treated fetal bovine serum (GIBCO), EGM-2,
pyruvic acid and antibiotics (‘‘hormone free medium’’) to avoid
any estrogenic activity and maintained for 24 hours. Then, culture
medium was eliminated and replaced by phenol red-free medium
199.
Cells were exposed to different concentrations (range: 0,01 –
100 nmol/L) of 17b-estradiol (Sigma, Alcobendas, Spain) by serial
dilutions of a stock solution with phenol red-free medium. The
pure anti-estrogen ICI182780 (1 mmol/L; Biogen, Madrid, Spain)
was used to evaluate whether the observed effects were mediated
by ER modulation. Control cells were exposed to the same
vehicles of estradiol (0.1% ethanol) or ICI182780 (0.1% DMSO).
All treatments were added in hormone free medium and
experiments were performed at 75–80 % of confluence.
RNA Isolation and Genechip Expression Analysis
To carry out the microarray experiments, HUVEC from 9
separate cultures were exposed to control (0.1% ethanol) and
1 nmol/L estradiol treatments for 24 h. Total cellular RNA was
extracted by using the TRIzolH reagent (Invitrogen, USA) following
the manufacturer’s instructions. RNA integrity was assayed by
means of the 2100 Bioanalizer (Agilent Technologies, Santa Clara,
CA, USA). Equal amounts of RNA extracted from 3 control- or 3
estradiol-treated cultured flasks obtained from three different
cultures were pooled, achieving three biological replicates of the
control and three that were treated with estradiol. Therefore, a total
number of 6 microarrays were developed (3 control pools, named
C1, C2, C3, and 3 estradiol-treated pools named E1, E2 and E3).
Five micrograms of total RNA were amplified and labeled
according to GeneChip Expression Analysis Technical Manual
(Affymetrix Ltd, UK). The concentration of biotinylated and
fragmented cRNA was measured using the 2100 Bioanalizer
(Agilent Technologies). Twenty micrograms of fragmented biotiny-
lated cRNA were used to prepare the hybridization cocktail and
subsequently hybridized for sixteen hours to the Human Genome
U133A plus 2.0 microarrays, which analyzes the expression level of
over 47000 transcripts and variants. Arrays were washed and
stained according to the EukGene_ws_2v5 in the Fluidics Station
(Affymetrix) and scanned using the GeneChip scanner 3000.
Affymetrix’s GeneChip Operating Software (GCOS, Affymetrix)
was used to obtain and analyze images.
Files obtained from GCOS (.cel) were used to analyze
significant changes in expression profiles of different experimental
groups using the dCHIP Analysis Software and the SpotFire
Decision Site software. Data were normalized using the Invariant
Set Method described earlier [15] and modeled using the PM/
MM model. Then, ANOVA was used to find significant changes
among experimental groups. False Discovery Rate (FDR) was used
to discriminate false positives in the multivariant system. Only
adjusted p-values ,0.05 were considered significant. Global
differences between different samples were measured by Principal
Component Analysis (PCA) and Linear Discrimination Analysis
(LDA). Hierarchical Cluster was used to analyze expression
profiles of different samples, and was carried out using UPGMA
(Unweighted Pair Group Method with Arithmetic Mean) analysis,
with an ordering function based on the input rank. Data are
represented as a dendrogram, with the closest branches of the tree
representing arrays with similar gene expression patterns. Gene
Onthology Browser (Nettaffyx Analysis Center, Affymetrix) was
used to classify genes according to functionality context. Finally,
relationships among data were screened using the Pathway
Architect software (Stratagene, La Joya, CA, USA). All data
discussed in this publication is MIAME compliant and that the
raw data has been deposited in NCBI’s Gene Expression Omnibus
[16], a MIAME compliant database, and are accessible through
GEO Series accession number GSE16683.
Network Identification and Canonical Pathway Analysis
List of genes significantly regulated by estrogen were analyzed
using Ingenuity Pathways Analysis (IPA) software (Ingenuity
Systems, Redwood City, CA, USA). IPA uses a variety of
computational algorithms to identify and establish cellular
networks that statistically fit the input gene list and expression
values from experiments. Data sets containing the Affymetrix
probe set identifiers and fold changes of genes were overlaid onto a
global molecular network developed from information contained
in the database. Networks were then algorithmically generated
based on their connectivity and a score was assigned. The score is
used to rank networks according to how relevant they are to the
genes in the input dataset. Each network or pathway was
arbitrarily set to have a maximum of 35 focus genes. Genes or
gene products are represented as nodes, and the biological
relationship between two nodes is represented as an edge. The
intensity of the node color indicates the degree of up- (red) or
down- (green) regulation.
Canonical pathways analysis identified the pathways, which
were most significant to the input data set. The significance of the
association between the data set and the canonical pathway was
determined based on two parameters: (1) a ratio of the number of
genes from the data set that map to the pathway divided by the
total number of genes that map to the canonical pathway and (2) a
P value calculated using Fischer’s exact test determining the
probability that the association between the genes in the data set
and the canonical pathway is due to chance alone.
Quantitative Real Time PCR (QRT-PCR) Assays
Reverse transcription (RT) was carried out using SuperScript
TM
II Synthesis System for RT–PCR (Invitrogen) by using a personal
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Germany). Different samples than that used for microarrays
experiments were used to perform the QRT-PCR assays. One
microgram of total RNA was reverse-transcribed to cDNA
following the manufacturer’s instructions. For each RT, a blank
was prepared using all the reagents except the RNA sample
(replaced with an equivalent volume of diethylpyrocarbonate
(DEPC)-treated water) and also used as non-template control in
real-time PCR experiments.
Quantitative real-time PCR (QRT-PCR) was done with SYBR-
Green PCR Master Mix or TaqMan Universal Mastermix
(Applied Biosystems, Fosters City, CA, USA). In the case of
DHCRA7, PLA2G4A and PLA2G4B, the PCR reaction mix was
prepared in 0.2 mL RNase free tubes by adding a volume of
TaqMan Universal PCR Master Mix and TaqMan Gene
Expression Assay (Table 1). The sample of cDNA obtained from
the RT was incorporated into the necessary quantity of DEPC-
treated water to get a final concentration of 40 ng approximately
(range: 10–100 ng). The GADPH gene was used as endogenous
control. The appropriate volume of each reaction mixture was
transferred to a reaction plate which was then placed in the
7900HT Fast Real-Time PCR System (Applied Biosystems) with
the appropriate thermal cycling conditions (50uC/2 min, 95uC/
10 min, 40 Cycles; 95uC/15 s, 6uC/1 min).
In the case of COX-1, COX-2, DDAH-1 and DDAH-2, a
QRT-PCR was performed using an ABI PRISM 7700 Sequence
Detection System (Applied Biosystems) with a heated lid (105uC),
an initial denaturation step at 95uC for 10 min, followed by 40
cycles of 95uC for 15 s and 60uC for 1 min. To amplify cDNA, the
RT samples were diluted 1/10. In each reaction, a total of 1 mL
from each RT tube was mixed with 12.5 mL of SYBR Green PCR
master mix (Applied Biosystems) containing nucleotides, Taq
DNA polymerase, MgCl2 and reaction buffer with SYBR green;
1.5 mLo f5mmol/L adequate primers and DEPC-treated water
were added to a final volume of 25 mL. In parallel, 5-fold serial
dilutions of well-known DNA concentrations were run as
calibration curves. Primers (Table 1) were designed using the
Primers Express Software (Applied Biosystems) and synthesized by
Custom Primers (Life Technologies, Barcelona, Spain).
Data were analysed with the ABI PRISM Sequence Detection
v. 1.7 analysis software (Perkin Elmer, Nieuwerkerk, The Nether-
lands). To validate a QRT-PCR, standard curves with r.0.95 and
slope values between 23.1 and 23.4 were required. Gene
expression was relative quantified based on the work of Pfaffl
[17]. In some samples, PCR bands were purified using a
MiniElute PCR Purification Kit (Qiagen, Valencia, CA, USA)
and then sequenced to prove that the amplified products
corresponded to previously published sequences. Agarose gel
electrophoreses were also performed to demonstrate that QRT-
PCR yielded a unique band.
Immunoblotting
HUVEC were treated in 25 cm
2 flasks for 24 hours with the
desired products. A volume of 150 mL of lysis buffer (0.1 % triton
X-100, 0.5 % sodium deoxicholate acid, 0.1 % Sodium Dodecyl
Sulphate (SDS), 0.1% phenylmethanesulphonylfluoride or phe-
nylmethylsulphonyl fluoride (PMSF), in 100 mL of phosphate
saline buffer (PBS) containing protease inhibitors: 1 mg/mL
leupeptin, 0.5 mg/mL pepstatin and 1 mg/mL bestatin) was added
and maintained at 4uC for 30 minutes. Then, cells were collected
using a cell scraper, boiled for 5 minutes and sonicated for 10
seconds. Protein content was measured [18] and samples were
frozen at –20uC until assay.
Equal amounts of protein (60–80 mg) were then separated by
10% of SDS-Polyacrylamide gel electrophoresis, and the protein
was transferred to PVDF sheets (Biorad, Spain). Immunostaining
was achieved using specific antibodies anti-ERa (sc-8002; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-ERb (sc-8974;
Santa Cruz Biotechnology), anti-COX-1 (cat 236003; Calbio-
chem, Germany), anti-COX-2 (cat 160107; Cayman Chemical),
anti-DDAH-I (PC716; Calbiochem) or anti-DDAH-II (PC717;
Calbiochem). Development was performed with alkaline-phos-
phatase-linked appropriate secondary antibodies (from Sigma),
followed with nitroblue tetrazolium (NBT)/5-Bromo-4-Chloro-3-
Indolyl Phosphate, p-toluidine salt (BCIP) color development
reaction. Blots were digitalized using a Gelprinter PLUS (TDI,
Madrid, Spain), and the densities of spots were analyzed with the
program Image Gauge 4.0 (Science Lab. 2001). Equivalent protein
Table 1. List of abbreviations and primers used for RT-PCR.
Gene Abbreviation Accession no. Custom Primer Sequence Fragment (bp)
Ciclooxigenase-1 COX-1 AF440204 Forward
Reverse
59-TACTCACAGTGCGCTCCAAC-39
59-GCAACTGCTTCTTCCCTTTG-39
168
Ciclooxigenase-2 COX-2 D28235 Forward
Reverse
59-ATCATAAGCAGGGCCAGCT-39
59-AAGGCGCAGTTTACGCTGTC-39
101
Dimethylarginine
dimethylaminohydrolase-1
DDAH-1 BC_033680 Forward
Reverse
59-GGACAAATCAACGAGGTGCT-39
59-TAGCGGTGGTCACTCATCTG-39
193
Dimethylarginine
dimethylaminohydrolase-2
DDAH-2 NM_013974 Forward
Reverse
59-GATCTGGCCAAAGCTCAAAG-3,
59-CAACCCAGGACGAAGAAAGA-39
573
Glyceraldehyde 3-phosphate
dehydrogenase
GADPH NM_002046 Forward
Reverse
59-CTGCTCCTCCTGTTCGACAGT-39
59-CCGTTGACTCCGACCTTCAC-39
100
Gene Gene Accesion no. TaqManH Gene Expression Assays Fragment (bp)
7-dehydrocholesterol reductase DHCR7 NM_001360.2 Hs00154732_m1 85
Phospholipase A2, group IVA PLA2G4A NM_024420.2 Hs00233352_m1 69
Phospholipase A2, group IVB PLA2G4B NM_005090.2 Hs00192661_m1 71
Glyceraldehyde 3-phosphate
dehydrogenase
GADPH NM_002046.3 endogenous control 122
doi:10.1371/journal.pone.0008242.t001
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probe set gene Accession
Control
mean
Control
SD
Estradiol
mean
Estradiol
SD
fold
change
P
value
212969_x_at hypothetical protein FLJ35827 BE222618 175,19 19,45 500,79 31,72 2,86 0,00342
223967_at angiopoietin-like 6 AF230330 30,98 8,72 86,64 5,75 2,8 0,02964
212064_x_at MYC-associated zinc finger protein (purine-binding
transcription factor)
AI471665 186,55 15,26 505,1 107,26 2,71 0,03497
203442_x_at hypothetical protein FLJ35827 AA478965 195,81 7,93 504,02 44,58 2,57 0,01052
224182_x_at sema domain, transmembrane domain (TM), and
cytoplasmic domain, (semaphorin) 6B
AF293363 68,13 17,43 169,76 12,74 2,49 0,01574
209079_x_at protocadherin gamma subfamily C, 3 AF152318 203,67 43,44 503,57 126,44 2,47 0,02558
227463_at angiotensin I converting enzyme
(peptidyl-dipeptidase A) 1
AW057540 69,93 12,41 170,95 17,15 2,44 0,03837
200707_at protein kinase C substrate 80K-H NM_002743 221,54 57,51 531,35 19,47 2,4 0,01438
240786_at Notch homolog 4 (Drosophila) AI341271 52,66 5,54 125 14,98 2,37 0,03691
204693_at CDC42 effector protein (Rho GTPase binding) 1 NM_007061 115,37 10,39 270,64 34,17 2,35 0,02829
201050_at phospholipase D3 NM_012268 274,9 34,99 647,38 19,89 2,35 0,00206
201396_s_at small glutamine-rich tetratricopeptide repeat
(TPR)-containing, alpha
NM_003021 166 16,76 389,34 54,20 2,35 0,01439
202017_at epoxide hydrolase 1, microsomal (xenobiotic) NM_000120 85,85 19,59 200,8 23,62 2,34 0,04111
227753_at hypothetical protein FLJ90586 R26843 42,02 6,69 98,19 3,76 2,34 0,01451
230698_at MRNA; cDNA DKFZp434H205 (from clone DKFZp434H205) AW072102 42,87 8,54 100,33 23,38 2,34 0,04531
208611_s_at spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) U83867 296,27 32,51 689,31 134,18 2,33 0,04892
209235_at chloride channel 7 AL031600 93,14 14,31 214,55 28,67 2,3 0,02221
211136_s_at cleft lip and palate associated transmembrane
protein 1
BC004865 97,85 34,88 223,39 2,62 2,28 0,03365
209427_at smoothelin AF064238 148,48 18,65 337,87 36,31 2,28 0,01198
200859_x_at filamin A, alpha (actin binding protein 280) NM_001456 837,96 143,55 1894,68 238,65 2,26 0,00676
224792_at tankyrase 1 binding protein 1, 182 kDa AL566438 83,59 21,44 188,84 16,91 2,26 0,03592
212127_at Ran GTPase activating protein 1 BE379408 148,57 70,00 322,79 15,80 2,17 0,04023
230112_at membrane-associated ring finger (C3HC4) 4 AB037820 181,14 83,07 391,8 35,54 2,16 0,02505
1570318_at Homo sapiens, clone IMAGE:4792986, mRNA BC030089 69,31 35,11 148,72 19,06 2,15 0,01849
205185_at serine protease inhibitor, Kazal type 5 NM_006846 160,85 55,95 346,46 19,02 2,15 0,01393
222206_s_at nicalin homolog (zebrafish) AA781143 91,29 8,04 195,18 9,50 2,14 0,0149
201373_at plectin 1, intermediate filament binding protein 500 kDa NM_000445 177,33 23,86 379,57 15,39 2,14 0,01277
1552667_a_at SH2 domain containing 3C NM_005489 95,12 13,48 203,46 16,70 2,14 0,04872
209051_s_at ral guanine nucleotide dissociation stimulator AF295773 96,35 14,24 205,2 3,85 2,13 0,02245
211564_s_at PDZ and LIM domain 4 BC003096 171,62 16,57 364,69 6,42 2,12 0,00636
240350_at Transcribed locus AI769817 70,76 23,81 148,99 13,00 2,11 0,0374
201797_s_at valyl-tRNA synthetase 2 NM_006295 95,72 15,28 201,89 17,35 2,11 0,03045
210428_s_at hepatocyte growth factor-regulated tyrosine kinase
substrate
AF260566 258,31 9,63 543,12 10,09 2,1 0,00539
202855_s_at solute carrier family 16 (monocarboxylic acid transporters),
member 3
AL513917 63,41 16,15 132,88 2,87 2,1 0,03614
202320_at general transcription factor IIIC, polypeptide 1, alpha
220 kDa
NM_001520 90,81 7,28 189,55 4,47 2,09 0,00867
218051_s_at hypothetical protein FLJ12442 NM_022908 321,65 53,09 667,99 45,65 2,08 0,00553
200808_s_at zyxin NM_003461 423,14 13,27 875,16 138,22 2,07 0,02725
216267_s_at placental protein 6 BF034906 114,34 23,47 234,61 1,02 2,05 0,02765
219270_at hypothetical protein MGC4504 NM_024111 128,82 44,89 262,36 58,64 2,04 0,04536
219922_s_at latent transforming growth factor beta binding protein 3 NM_021070 323,66 30,45 661,67 37,35 2,04 0,01075
1564494_s_at procollagen-proline, 2-oxoglutarate 4-dioxygenase
(proline 4-hydroxylase), beta polypeptide
AK075503 174,37 52,22 355,76 10,91 2,04 0,04303
201251_at pyruvate kinase, muscle NM_002654 417,25 18,67 851,66 107,61 2,04 0,02554
45714_at host cell factor C1 regulator 1 (XPO1 dependant) AA436930 136,61 17,78 276,98 20,76 2,03 0,02748
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Control
mean
Control
SD
Estradiol
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Estradiol
SD
fold
change
P
value
212359_s_at KIAA0913 W89120 155,23 17,17 314,75 29,07 2,03 0,01367
201168_x_at Rho GDP dissociation inhibitor (GDI) alpha NM_004309 384,7 36,45 780,38 119,07 2,03 0,023
223383_at zinc and ring finger 1 AL136903 95,87 25,43 195,09 6,64 2,03 0,04785
215909_x_at misshapen-like kinase 1 (zebrafish) AL157418 145,34 48,17 294,11 68,43 2,02 0,01318
35265_at fragile X mental retardation, autosomal homolog 2 AF044263 100,19 6,16 201,48 3,24 2,01 0,01011
226367_at Jumonji, AT rich interactive domain 1A (RBBP2-like) AA854032 57,11 11,39 114,98 15,75 2,01 0,04725
229192_s_at tubulin-specific chaperone d AL096745 170,61 43,32 342,84 9,29 2,01 0,02167
218522_s_at BPY2 interacting protein 1 NM_018174 165,12 25,92 330,46 5,94 2 0,01544
200766_at cathepsin D (lysosomal aspartyl protease) NM_001909 113,56 1,19 227,52 15,59 2 0,02324
222155_s_at G protein-coupled receptor 172A AK021918 74,97 10,34 149,89 2,16 2 0,01724
227347_x_at hairy and enhancer of split 4 (Drosophila) NM_021170 79,62 26,99 159,32 25,99 2 0,03086
215807_s_at plexin B1 AV693216 72,17 16,35 144,65 1,99 2 0,03366
202161_at protein kinase N1 NM_002741 236,28 21,45 472,79 10,07 2 0,0105
217937_s_at histone deacetylase 7A NM_016596 215,95 32,53 429,04 8,40 1,99 0,01042
209166_s_at mannosidase, alpha, class 2B, member 1 U68567 199,46 45,12 396,59 46,73 1,99 0,01271
212968_at radical fringe homolog (Drosophila) BF940276 159,88 10,60 317,92 31,31 1,99 0,01304
209651_at transforming growth factor beta 1 induced transcript 1 BC001830 934,12 83,13 1863,42 337,88 1,99 0,02541
203926_x_at ATP synthase, H+ transporting, mitochondrial F1 complex,
delta subunit
NM_001687 330,84 24,63 655,04 26,25 1,98 0,00858
208890_s_at plexin B2 BC004542 258,45 52,59 510,68 26,53 1,98 0,0126
217007_s_at a disintegrin and metalloproteinase domain 15 (metargidin) AK000667 101,77 21,65 200,18 6,12 1,97 0,02402
201360_at cystatin C (amyloid angiopathy and cerebral hemorrhage) NM_000099 384,94 8,11 758,71 49,24 1,97 0,01031
223050_s_at F-box and WD-40 domain protein 5 BC000850 107,78 10,49 212,4 22,07 1,97 0,02375
208132_x_at HLA-B associated transcript 2 NM_004638 117,46 6,61 230,97 11,34 1,97 0,01343
201264_at coatomer protein complex, subunit epsilon NM_007263 221,17 57,65 434,02 18,52 1,96 0,04857
210622_x_at cyclin-dependent kinase (CDC2-like) 10 AF153430 56,4 9,55 110,79 6,37 1,96 0,04874
209729_at growth arrest-specific 2 like 1 BC001782 133,53 13,55 261,57 28,58 1,96 0,02885
201102_s_at phosphofructokinase, liver NM_002626 201,25 8,94 394,24 6,59 1,96 0,0074
201281_at adhesion regulating molecule 1 NM_007002 349,38 56,97 679,65 108,43 1,95 0,02532
221009_s_at angiopoietin-like 4 NM_016109 224,97 19,81 438,78 85,29 1,95 0,03765
214175_x_at PDZ and LIM domain 4 AI254547 264,5 24,73 514,92 27,01 1,95 0,00287
203055_s_at Rho guanine nucleotide exchange factor (GEF) 1 NM_004706 136,27 20,25 265,87 27,67 1,95 0,03729
201079_at synaptogyrin 2 NM_004710 423,03 23,29 826,04 79,77 1,95 0,01402
244017_at Tax1 (human T-cell leukemia virus type I) binding protein 1 AI218142 73,03 13,78 142,55 9,52 1,95 0,04703
40829_at WD and tetratricopeptide repeats 1 AB028960 114,71 11,89 223,14 33,03 1,95 0,0312
201945_at furin (paired basic amino acid cleaving enzyme) NM_002569 186,14 26,50 361,57 25,35 1,94 0,04325
222003_s_at dedicator of cytokinesis 6 BE857715 141,94 34,44 273,32 3,82 1,93 0,02743
200747_s_at nuclear mitotic apparatus protein 1 NM_006185 177,05 30,13 342,53 1,12 1,93 0,02273
218494_s_at SLC2A4 regulator NM_020062 164,72 22,13 317,53 22,57 1,93 0,01816
217729_s_at amino-terminal enhancer of split NM_001130 200,99 28,32 386,1 14,93 1,92 0,02748
208978_at cysteine-rich protein 2 U36190 522,29 187,11 1003,95 51,34 1,92 0,02812
204355_at DEAH (Asp-Glu-Ala-His) box polypeptide 30 NM_014966 216,71 19,48 415,91 36,10 1,92 0,0208
226307_at transducer of regulated cAMP response element-binding
protein (CREB) 2
AW504757 183,05 15,21 351,43 67,63 1,92 0,03444
204431_at transducin-like enhancer of split 2 (E(sp1) homolog,
Drosophila)
NM_003260 191,78 47,68 368,22 11,00 1,92 0,03922
223179_at yippee-like 3 (Drosophila) BC005009 131,63 33,05 253,07 4,77 1,92 0,037
214679_x_at guanine nucleotide binding protein (G protein),
alpha 11 (Gq class)
AL110227 191,38 15,11 365,57 52,83 1,91 0,0273
205740_s_at hypothetical protein MGC10433 NM_024321 140,3 11,74 268,07 12,03 1,91 0,01253
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208110_x_at mediator of RNA polymerase II transcription, subunit 25
homolog (yeast)
NM_030973 120,74 11,71 231,04 22,23 1,91 0,01676
227557_at scavenger receptor class F, member 2 AI127800 69,68 7,47 133,39 3,34 1,91 0,01744
203254_s_at talin 1 NM_006289 302,17 24,41 576,14 97,40 1,91 0,02533
225868_at tripartite motif-containing 47 AW249467 260,23 15,67 497,05 68,76 1,91 0,03083
217912_at PP3111 protein NM_022156 301,95 39,31 573,85 26,94 1,9 0,01004
219802_at hypothetical protein FLJ22028 NM_024854 247,99 16,16 129,67 17,21 21,91 0,02723
220553_s_at PRP39 pre-mRNA processing factor 39 homolog (yeast) NM_018333 348,68 49,92 182,71 2,12 21,91 0,03766
222129_at Chromosome 2 open reading frame 17 AK026155 475,98 66,26 248,54 70,12 21,92 0,00982
209525_at Hepatoma-derived growth factor, related protein 3 BG285017 399,99 13,42 208,81 72,27 21,92 0,04455
214101_s_at Aminopeptidase puromycin sensitive BG153399 518,57 14,39 267,18 60,68 21,94 0,0284
201694_s_at early growth response 1 NM_001964 912,16 116,79 467,6 123,62 21,95 0,00691
1559391_s_at UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,
polypeptide 5
AI084451 301,03 26,43 154,27 23,44 21,95 0,03508
228193_s_at Response gene to complement 32 AI744499 250,61 22,33 127,67 56,97 21,96 0,04859
1556019_at hypothetical protein LOC144874 BE502765 1173,2 95,58 596,16 173,35 21,97 0,01607
230206_at Dedicator of cytokinesis 5 AI692645 158,44 36,03 79,79 11,89 21,99 0,0427
229397_s_at Glucocorticoid receptor DNA binding factor 1 AI275597 147,21 12,14 74,15 11,65 21,99 0,04387
1555272_at hypothetical protein LOC285927 BC044242 618,29 51,90 310,14 155,33 21,99 0,04207
229420_at Similar to 60S ribosomal protein L23a AI557425 1107,1 154,44 557,27 237,67 21,99 0,02051
219375_at choline NM_006090 433,25 69,86 216,49 13,98 22 0,02552
229787_s_at O-linked N-acetylglucosamine (GlcNAc) transferase AI742039 407,25 82,20 203,63 53,17 22 0,01368
216246_at Ribosomal protein S20 AF113008 718,07 204,97 359,53 80,17 22 0,03995
1552664_at folliculin NM_144997 315,35 34,67 156,57 10,05 22,01 0,01331
1558504_at Similar to hypothetical protein LOC284701 AF086554 161,72 10,90 79,91 27,44 22,02 0,0256
235918_x_at gb:AL559474 AL559474 120,53 29,85 59,5 8,65 22,03 0,0485
225920_at hypothetical protein LOC148413 AW452640 735,04 27,11 362,24 119,58 22,03 0,0301
229538_s_at IQ motif containing GTPase activating protein 3 AW271106 161,6 20,81 79,43 18,07 22,03 0,01163
221910_at hypothetical protein LOC221810 BF131965 152,28 9,84 74,67 20,84 22,04 0,03427
229630_s_at Wilms tumor 1 associated protein AU147416 1450,7 50,43 712,54 184,74 22,04 0,01547
218737_at sno, strawberry notch homolog 1 (Drosophila) NM_018183 116,38 20,25 56,81 4,58 22,05 0,04833
1561481_at Homo sapiens, clone IMAGE:4827393, mRNA BC034606 271,34 79,40 131,55 34,12 22,06 0,04476
206448_at zinc finger protein 365 NM_014951 198,83 24,74 96,55 1,99 22,06 0,02286
238002_at golgi phosphoprotein 4 BF342391 886,71 127,65 428,76 97,91 22,07 0,00471
204863_s_at interleukin 6 signal transducer (gp130, oncostatin M
receptor)
BE856546 135,03 26,71 65,32 18,57 22,07 0,03394
243159_x_at Myosin X AI247495 363,27 42,74 175,08 38,42 22,07 0,00176
234344_at RAP2C, member of RAS oncogene family AF093744 267,15 21,81 128,37 30,05 22,08 0,01344
214038_at chemokine (C-C motif) ligand 8 AI984980 168,57 27,35 79,65 5,77 22,12 0,02801
242467_at Full-length cDNA clone CS0DJ012YP16 of T cells (Jurkat
cell line)
BF433200 213,36 47,26 100,12 8,02 22,13 0,04832
224346_at gb:AF116671.1 AF116671 245,39 57,23 114,94 37,07 22,13 0,01828
241872_at Hypothetical protein DKFZp761D221 AI149963 354,96 59,53 165,78 12,12 22,14 0,0268
202425_x_at protein phosphatase 3 (formerly 2B), catalytic subunit,
alpha isoform (calcineurin A alpha)
NM_000944 837,16 7,08 391,06 61,98 22,14 0,0101
235999_at Heterogeneous nuclear ribonucleoprotein D (AU-rich
element RNA binding protein 1, 37 kDa)
AA863112 136,83 22,52 63,56 19,97 22,15 0,02282
217550_at Activating transcription factor 6 AA576497 517,27 117,65 238,89 64,33 22,17 0,0154
1565765_x_at Hypothetical protein FLJ14834 AL832478 618,76 41,26 285,03 110,71 22,17 0,02286
219138_at ribosomal protein L14 BC000606 568,98 102,87 262,25 146,81 22,17 0,02015
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228545_at Zinc finger protein 148 (pHZ-52) AI016784 166,27 30,20 76,32 7,03 22,18 0,04509
239376_at CDNA clone IMAGE:4333081, partial cds AA489041 244,11 20,12 111,45 30,03 22,19 0,04759
201159_s_at N-myristoyltransferase 1 NM_021079 98,32 10,08 44,9 7,35 22,19 0,04858
240145_at Transcribed locus, moderately similar to NP_008471.1
Canis familiaris ND1 gene
AW628059 118,98 22,05 54,36 14,20 22,19 0,04816
238608_at Laminin, beta 1 AI174988 301,52 55,25 136,99 40,66 22,2 0,00821
244356_at Protein tyrosine phosphatase, non-receptor type 12 AL079909 133,28 14,99 60,41 0,79 22,21 0,03174
244757_at Cytochrome P450, family 2, subfamily R, polypeptide 1 AI692525 98,81 17,21 44,57 21,09 22,22 0,01478
204296_at gb:NM_021196.1 NM_021196 109,35 26,51 49,24 7,95 22,22 0,04929
224250_s_at SECIS binding protein 2 BC001189 261,83 60,16 117,72 9,62 22,22 0,04101
212952_at Calreticulin AA910371 1511,5 396,05 675,96 133,87 22,24 0,03178
243993_at PCTAIRE protein kinase 2 AA436887 393,92 77,35 176,13 6,16 22,24 0,03576
232118_at Chromosome 20 open reading frame 155 R33735 298,56 7,84 132,41 47,33 22,25 0,03847
202028_s_at gb:BC000603.1 BC000603 2150,5 446,40 939,35 211,88 22,29 0,01471
209207_s_at SEC22 vesicle trafficking protein-like 1 (S. cerevisiae) BC001364 705,55 75,30 307,12 77,55 22,3 0,00335
242560_at Fanconi anemia, complementation group D2 AA579890 121,37 27,26 52,58 26,19 22,31 0,04905
226085_at Chromobox homolog 5 (HP1 alpha homolog, Drosophila) AA181060 674,11 177,98 288,47 107,20 22,34 0,0154
206438_x_at hypothetical protein FLJ12975 NM_024809 488,81 19,84 207,71 74,71 22,35 0,03745
1560402_at growth arrest-specific 5 BF336936 430,65 47,57 182,35 90,17 22,36 0,01151
225116_at Homeodomain interacting protein kinase 2 AW300045 539,53 90,42 228,41 79,96 22,36 0,01139
214395_x_at Eukaryotic translation elongation factor 1 delta (guanine
nucleotide exchange protein)
AI335509 194,14 37,67 82,06 44,72 22,37 0,03623
1558019_at Dystonin BC020911 327,5 63,55 137,33 30,17 22,38 0,01177
1564072_at gb:AK025690.1 AK025690 1020,1 152,50 428,9 82,66 22,38 0,03267
226643_s_at NudC domain containing 2 AI291200 373,57 27,38 156,7 79,47 22,38 0,02316
231393_x_at Zinc finger protein 297B AW237165 158,76 22,10 66,09 26,02 22,4 0,03737
231370_at Protein phosphatase 1A (formerly 2C),
magnesium-dependent, alpha isoform
AI701170 264,16 54,30 108,58 26,09 22,43 0,01432
1563283_at Homo sapiens, clone IMAGE:4828909, mRNA BG718722 843,46 98,58 345,82 109,30 22,44 0,00876
213426_s_at caveolin 2 AA150110 470,58 114,98 189,36 102,20 22,49 0,0063
213734_at WD repeat and SOCS box-containing 2 BG260658 740,32 176,82 296,21 80,29 22,5 0,01662
229165_at Mitochondrial ribosomal protein L12 BF433010 162,11 10,83 64,37 23,71 22,52 0,03196
202648_at ribosomal protein S19 BC000023 529,75 51,94 209,85 38,50 22,52 0,00463
220839_at methyltransferase like 5 NM_014168 237,93 77,58 93,29 36,86 22,55 0,04023
242485_at PTK2 protein tyrosine kinase 2 AW178807 166,68 31,29 64,65 10,50 22,58 0,0348
230820_at SMAD specific E3 ubiquitin protein ligase 2 BF111169 1460,4 212,19 549,25 150,26 22,66 0,00218
222027_at Nuclear ubiquitous casein kinase and cyclin-dependent
kinase substrate
AW515443 111,81 7,14 41,65 10,47 22,68 0,03024
212649_at gb:AL079292.1 AL079292 202,52 44,29 75,22 39,30 22,69 0,02723
228477_at Hypothetical protein FLJ10154 R53084 1465,2 151,71 541,96 142,16 22,7 0,00166
239859_x_at ATP synthase, H+ transporting, mitochondrial F0 complex,
subunit s (factor B)
AW140122 93,77 4,18 33,72 15,53 22,78 0,04668
210758_at PC4 and SFRS1 interacting protein 1 AF098482 444,61 36,70 156,69 37,48 22,84 0,02343
1557830_at Cyclin J AW063658 367,31 19,61 126,36 23,00 22,91 0,00916
1559521_at MRNA full length insert cDNA clone EUROIMAGE 29093 AL355741 258,03 21,91 84,38 45,58 23,06 0,02554
200908_s_at ribosomal protein, large P2 BC005354 575,68 24,55 187,15 108,90 23,08 0,02087
224375_at gb:AF271776.1 AF271776 795,28 79,08 248,14 145,83 23,2 0,01506
233204_at Hypothetical protein MGC40405 AA115105 107,54 17,25 30,82 10,88 23,49 0,02822
230084_at solute carrier family 30 (zinc transporter), member 2 BF510698 814,56 203,67 232,49 146,26 23,5 0,01187
232351_at CDNA FLJ12246 fis, clone MAMMA1001343 AK022308 158,29 39,36 45,15 10,32 23,51 0,03121
Table 2. Cont.
Estradiol and Gene Expression
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8242l-
probe set gene Accession
Control
mean
Control
SD
Estradiol
mean
Estradiol
SD
fold
change
P
value
243885_x_at Latexin AA526937 92,06 29,95 26,17 11,58 23,52 0,03092
241617_x_at gb:BE961949 BE961949 93,34 23,47 25,35 11,78 23,68 0,02206
214313_s_at Eukaryotic translation initiation factor 5B BE138647 113,14 16,37 29,69 14,69 23,81 0,02274
1553749_at hypothetical protein MGC33371 NM_144664 194,53 71,06 50,5 27,11 23,85 0,04744
1553575_at gb:NM_173714.1 NM_173714 440,06 81,16 108,49 27,98 24,06 0,01314
220787_at gb:NM_018629.1 NM_018629 72,95 6,02 17,61 5,48 24,14 0,01972
213813_x_at gb:AI345238 AI345238 232,05 35,44 55 23,58 24,22 0,00713
233047_at hypothetical protein LOC90167 AL161984 451,93 128,65 84,7 14,81 25,34 0,03067
doi:10.1371/journal.pone.0008242.t002
Table 2. Cont.
Figure 1. Supervised hierarchical cluster of HUVEC gene expression changes in response to estradiol. 263 probe sets of genes
significantly regulated by greater than 1.8-fold change were used for 2D hierarchical clustering. Each row represents an individual probe set, and each
column represents a pool of cells (C1, C2 and C3: control samples; E1, E2 and E3: estradiol-treated samples). 129 up- (red) or 134 down- (green) were
regulated (P value,0.05).
doi:10.1371/journal.pone.0008242.g001
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(Sigma).
Prostacyclin Assay
After treatment with the desired products, medium was collected
and stored at –20uC until prostacyclin was measured. Culture wells
were then washed with PBS and adherent cells were collected in
0.5 N NaOH for protein determination by the modified Lowry’s
method using bovine serum albumin as standard [18].
The amount of prostacyclin produced, calculated as the concentra-
tion of stable hydrolysis product, 6-keto-prostaglandin-F1a,w a s
assessed in duplicate by a commercial EIA kit (Cayman Chemical).
Prostacyclin production was expressed as ng prostacyclin/mg protein.
Isolation and Measurement of Asymmetric
Dimethylarginine (ADMA)
After 24 hours of incubation with the desired treatments,
medium was collected and stored at –20uC until asymmetric
dimethylarginine (ADMA), a major endogenous inhibitor of nitric
oxide synthase (NOS), quantification. Culture wells were then
washed with PBS and adherent cells were collected in 0.5 N
NaOH solution for protein determination [18].
Measurement of ADMA was accomplished by high-perfor-
mance liquid chromatography (HPLC) as described earlier [19].
In brief, ADMA from 1 mL of culture medium was purified with
Bond Elut SCX columns (Varian Inc., Palo Alto, CA, USA) and
eluted with 4 mL of methanol containing 30% distilled water and
2% triethylamine. The eluent was then evaporated to dryness at
60uC, and the dried extract was redissolved in running buffer.
HPLC was carried out on a Shimadzu chromatography system
(Shimadzu Corporation, Kyoto, Japan). Separation of ADMA was
achieved with a 25064.6-mm (inner diameter), 5-mm ‘‘Kromasil
C18’’ analytical column (Scharlau, Barcelona, Spain) using
25 mM phosphoric acid containing 10 mM hexane sulphonic
acid and 1 % [v/v] acetonitrile, pH 5.0. The analysis was carried
out at a flow rate of 1.3 mL/min and the absorbance monitored at
200 nm. Concentrations of ADMA in the samples were deter-
mined by comparison with standards (Sigma, Alcobendas, Spain).
ADMA production was expressed as nmol/mg protein.
Nitric Oxide (NO) Production
After 24 hours of incubation with the desired treatments, cells
were washed and incubated with HEPES buffer (5 mM HEPES
containing (in mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2 and 10
glucose, pH adjusted to 7.4), for 120 min. Then, incubation
Figure 2. Supervised principal component analysis (PCA). Microarray hybridizations were performed using total RNA from HUVEC exposed to
1 nmol/L estradiol for 24 h. The gene expression profiles of 3 pools of control cells (blue) and 3 pools of cells treated with estradiol 1 nmol/L (red)
were compared using PCA. The three-dimensional (3D) plot view of gene expression data (including all probe sets on U133 Plus 2.0 GeneChip) is
shown, with respect to their correlation to the first three principal components.
doi:10.1371/journal.pone.0008242.g002
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Category Process Annotation Significance Molecules
Cellular Growth and Proliferation growth of cells 0,0000 47
growth of kidney cell lines 0,0102 4
growth of fibrosarcoma cell lines 0,0103 2
growth of eukaryotic cells 0,0111 25
arrest in growth of pre-B lymphocytes 0,0143 1
growth of colon cell lines 0,0143 1
growth of hepatoma cell lines 0,0147 3
growth of cell lines 0,0156 20
growth of embryonic cell lines 0,0158 3
growth of lymphoma cell lines 0,0170 3
growth of melanoma cells 0,0215 2
growth of leukemia cell lines 0,0218 4
arrest in growth of cells 0,0266 6
colony formation 0,0002 16
colony formation of cells 0,0002 16
colony formation of eukaryotic cells 0,0003 15
colony formation of tumor cell lines 0,0004 10
colony formation of carcinoma cell lines 0,0020 3
colony formation of cell lines 0,0020 11
colony formation of red blood cells 0,0059 3
colony formation of blood cells 0,0062 5
colony formation of lung cancer cell lines 0,0073 3
colony formation of bone cancer cell lines 0,0086 2
colony formation of leukemia cell lines 0,0086 2
colony formation of connective tissue cells 0,0098 3
colony formation of erythroid cells 0,0103 2
colony formation of stromal cells 0,0143 1
colony formation of erythroid cell lines 0,0144 2
colony formation of bone marrow cells 0,0149 4
colony formation of lymphatic system cells 0,0165 4
colony formation of myeloid cells 0,0251 3
colony formation of prostate cancer cell lines 0,0270 2
proliferation of endothelial cells 0,0015 7
arrest in proliferation of bone cancer cell lines 0,0143 1
proliferation of granulocytes 0,0215 2
formation of osteoclast-like cells 0,0123 2
formation of epithelial cell lines 0,0143 1
formation of lung cancer cell lines 0,0143 1
formation of macrophages 0,0215 2
formation of blood cells 0,0266 3
induction of mesenchymal cells 0,0143 1
inhibition of endothelial cell lines 0,0143 1
inhibition of endothelial cells 0,0143 1
inhibition of ovarian cancer cell lines 0,0143 1
inhibition of smooth muscle cells 0,0143 1
stimulation of progenitor cells 0,0143 1
suppression of fibroblast cell lines 0,0143 1
suppression of lung cell lines 0,0143 1
expansion of hematopoietic progenitor cells 0,0190 2
Cell-To-Cell Signaling and Interaction binding of stem cells 0,0002 2
Estradiol and Gene Expression
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binding of female germ cells 0,0054 2
binding of embryonic stem cells 0,0143 1
binding of stromal cell lines 0,0143 1
binding of sperm 0,0242 2
adhesion of cells 0,0012 22
adhesion of tumor cell lines 0,0176 7
attachment of brain cancer cell lines 0,0020 2
attachment of tumor cell lines 0,0073 3
attachment of intestinal cell lines 0,0143 1
attachment of spermatids 0,0143 1
attachment of spermatocytes 0,0143 1
attachment of cell lines 0,0170 3
attachment of eukaryotic cells 0,0280 4
accumulation of focal adhesions 0,0143 1
activation of carcinoma cell lines 0,0143 1
contact growth inhibition of fibrosarcoma cell lines 0,0143 1
development of intercalated disks 0,0143 1
disassembly of adherens junctions 0,0143 1
induction of mesenchymal cells 0,0143 1
maintenance of focal adhesions 0,0143 1
production of cell-associated matrix 0,0143 1
response of breast cancer cell lines 0,0143 1
sensitization of leukocyte cell lines 0,0143 1
stimulation of progenitor cells 0,0143 1
suppression of fibroblast cell lines 0,0143 1
suppression of lung cell lines 0,0143 1
Cellular Compromise fragmentation of vesicles 0,0002 2
fragmentation of hepatocytes 0,0143 1
degeneration of epithelial cells 0,0012 2
degeneration of cells 0,0061 6
degeneration of keratinocytes 0,0143 1
degeneration of renal tubular epithelial cells 0,0143 1
shrinkage of cells 0,0086 2
depletion of podocytes 0,0143 1
disassembly of adherens junctions 0,0143 1
disruption of PML nuclear bodies 0,0143 1
disruption of spindle pole 0,0143 1
Cardiovascular System Development and
Function
development of vascular tissue 0,0002 3
development of blood vessel 0,0005 15
proliferation of endothelial cells 0,0015 7
cell flattening of endothelial cells 0,0143 1
concentration of blood vessel 0,0143 1
inhibition of endothelial cell lines 0,0143 1
inhibition of endothelial cells 0,0143 1
length of endothelial tube 0,0143 1
migration of cardiomyocytes 0,0143 1
muscularization of pulmonary artery 0,0143 1
thickness of right ventricle of heart 0,0143 1
angiogenesis 0,0182 10
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angiogenesis of tumor 0,0251 3
vasculogenesis 0,0236 3
Carbohydrate Metabolism modification of polysaccharide 0,0002 4
modification of N-glycan 0,0003 3
modification of carbohydrate 0,0181 4
metabolism of glucose-6-phosphate 0,0012 2
moiety attachment of polysaccharide 0,0041 2
moiety attachment of carbohydrate 0,0166 2
processing of N-glycan 0,0069 2
galactosylation of N-glycan 0,0143 1
utilization of glucose-6-phosphate 0,0143 1
Skeletal and Muscular System
Development and Function
area of muscle cells 0,0006 3
formation of osteoclast-like cells 0,0123 2
development of intercalated disks 0,0143 1
development of tracheal ring 0,0143 1
inhibition of smooth muscle cells 0,0143 1
length of skeleton 0,0143 1
migration of cardiomyocytes 0,0143 1
morphology of skeletal muscle 0,0143 1
muscularization of pulmonary artery 0,0143 1
size of medullary cavity 0,0143 1
myogenesis of organism 0,0215 2
differentiation of bone cell lines 0,0280 4
Cellular Assembly and Organization accumulation of actin filaments 0,0012 2
accumulation of filaments 0,0054 2
accumulation of focal adhesions 0,0143 1
assembly of vesicles 0,0030 2
assembly of actin filaments 0,0090 4
cross-linkage of actin filaments 0,0030 2
cross-linkage of microfilaments 0,0143 1
biogenesis of actin cytoskeleton 0,0065 5
biogenesis of mitochondria 0,0144 2
biogenesis of cytoskeleton 0,0167 6
association of actin cytoskeleton 0,0143 1
deposition of collagen fibrils 0,0143 1
deposition of reticulin fiber networks 0,0143 1
detachment of desmin filament 0,0143 1
development of intercalated disks 0,0143 1
development of mitochondria 0,0190 2
disruption of PML nuclear bodies 0,0143 1
disruption of spindle pole 0,0143 1
immobilization of actin filaments 0,0143 1
maturation of olfactory glomeruli 0,0143 1
organization of cell cortex 0,0143 1
organization of microtubules 0,0242 2
polymerization of actin stress fibers 0,0143 1
production of cell-associated matrix 0,0143 1
quantity of mitochondrial contact sites 0,0143 1
quantity of multivesicular bodies 0,0143 1
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formation of actin filaments 0,0145 7
formation of filaments 0,0254 8
formation of axons 0,0270 2
stabilization of filaments 0,0251 3
reorganization of actin 0,0270 2
Cellular Movement chemotaxis of lymphocytes 0,0025 6
chemotaxis of mononuclear leukocytes 0,0030 7
chemotaxis of natural killer cells 0,0042 3
chemotaxis of T lymphocytes 0,0134 4
chemotaxis of leukocytes 0,0227 7
chemotaxis of blood cells 0,0275 7
migration of dermal fibroblasts 0,0030 2
migration of trophoblast cells 0,0054 2
migration of embryonic cells 0,0127 4
migration of cardiomyocytes 0,0143 1
migration of endodermal cells 0,0143 1
homing of lymphocytes 0,0041 6
homing of mononuclear leukocytes 0,0045 7
homing of T lymphocytes 0,0165 4
cell movement 0,0048 32
cell movement of dermal fibroblasts 0,0069 2
cell movement of natural killer cells 0,0098 3
cell movement of embryonic cells 0,0141 4
cell movement of lymphocytes 0,0147 8
cell movement of mononuclear leukocytes 0,0177 9
release of cells 0,0086 2
infiltration of hairy leukemia cells 0,0143 1
locomotion of neutrophils 0,0143 1
scattering of pancreatic cancer cells 0,0143 1
scattering of squamous carcinoma cells 0,0143 1
translocation of spermatids 0,0143 1
haptotaxis of tumor cell lines 0,0144 2
Cell Death cell death of fibroblast cell lines 0,0002 13
cell death of cell lines 0,0019 32
cell death of kidney cell lines 0,0019 9
cell death of prostate cell lines 0,0041 2
cell death of eukaryotic cells 0,0051 40
cell death 0,0052 47
cell death of embryonic cell lines 0,0067 7
cell death of neuroblastoma cell lines 0,0109 5
cell death of thyroid cells 0,0123 2
cell death of muscle cells 0,0133 6
cell death of endothelial cell lines 0,0165 4
cell death of epithelial cell lines 0,0185 7
delay in cell death of cell lines 0,0190 2
cell death of eosinophils 0,0215 2
cell death of nervous tissue cell lines 0,0266 3
cell death of splenocytes 0,0270 2
regeneration of blood cells 0,0012 2
regeneration of blood platelets 0,0143 1
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regeneration of hematopoietic progenitor cells 0,0143 1
regeneration of red blood cells 0,0143 1
apoptosis of kidney cell lines 0,0014 8
apoptosis of prostate cell lines 0,0020 2
apoptosis of embryonic cell lines 0,0066 6
delay in apoptosis of tumor cell lines 0,0103 2
apoptosis of thyroid cells 0,0123 2
apoptosis of fibroblast cell lines 0,0123 8
apoptosis of granulocyte-macrophage progenitor cells 0,0143 1
apoptosis of liver cells 0,0157 4
delay in apoptosis of cell lines 0,0190 2
apoptosis of epithelial cell lines 0,0195 6
apoptosis 0,0200 39
apoptosis of eosinophils 0,0215 2
apoptosis of splenocytes 0,0215 2
apoptosis of muscle cells 0,0227 5
apoptosis of hippocampal cells 0,0242 2
apoptosis of cerebral cortex cells 0,0266 3
apoptosis of stomach cancer cell lines 0,0270 2
colony survival of eukaryotic cells 0,0047 3
colony survival 0,0059 3
colony survival of cells 0,0059 3
colony survival of lymphoma cell lines 0,0143 1
cell viability of neuroblastoma cell lines 0,0086 2
survival of endocrine cells 0,0103 2
survival of germ cells 0,0123 2
survival of gonadal cells 0,0144 2
survival of pheochromocytoma cell lines 0,0242 2
survival of hematopoietic cells 0,0270 2
Lipid Metabolism biosynthesis of phosphatidylinositol 0,0041 2
biosynthesis of phosphatidic acid 0,0042 3
biosynthesis of phospholipid 0,0116 3
biosynthesis of dolichol monophosphate mannose 0,0143 1
binding of 1-alpha, 25-dihydroxy vitamin D3 0,0143 1
formation of 5(S)-HETE 0,0143 1
production of 25-hydroxy-vitamin D3 0,0143 1
production of cholecalciferol 0,0143 1
reduction of ceramide 0,0143 1
utilization of triacylglycerol 0,0143 1
Cardiovascular Disease hypoplasia of myocardium 0,0054 2
fibrosis of portal artery 0,0143 1
muscular dystrophy of cardiac muscle 0,0143 1
tetralogy of Fallot of mice 0,0143 1
cell death of endothelial cell lines 0,0165 4
cardiovascular disorder of heart 0,0195 3
Cell Signaling cell surface receptor linked signal transduction 0,0063 14
suppression of nitric oxide 0,0143 1
androgen receptor signaling pathway 0,0166 2
Metabolic Disease amyloidosis 0,0106 3
familial partial lipodystrophy type 2 0,0143 1
Table 3. Cont.
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adherent cells were collected in 0.5 N NaOH solution for protein
determination [18].
Endothelial NO production was determined in culture
medium using the ISONOP nitric oxide sensor (World Precision
Instruments, Sarasota, FL, USA), an amperometric sensor
specific for NO, as described earlier [19]. A chemical titration
calibration was performed with use of an acidic iodide solution
(0.1 mol/l H2SO4,0 . 1 4m o l / lK 2SO4, 0.1 mol/l KI) against
varied volumes of KNO2.N Ow a sf o r m e ds t o ichiometrically and
measured directly. The quantity of NO was expressed as nmol/
mg protein.
Statistical Analysis
V a l u e ss h o w ni nt h et e x ta n df i g u r e sa r em e a n6 SEM.
ANOVA test was applied for comparisons of mean, and then
Bonferroni’s test wasp e r f o r m e d .Pv a l u e s ,0.05 were considered
significant. The statistical analysis was carried out using the
Prism 4 software (GraphPad Software Inc., San Diego, CA,
USA).
Category Process Annotation Significance Molecules
pseudohypoparathyroidism, type 1B 0,0143 1
Endocrine System Disorders apoptosis of thyroid cells 0,0123 2
cell death of thyroid cells 0,0123 2
differentiation of pancreatic cancer cells 0,0143 1
McCune-Albright syndrome 0,0143 1
pseudohypoparathyroidism, type 1B 0,0143 1
scattering of pancreatic cancer cells 0,0143 1
spontaneous autoimmune thyroiditis of mice 0,0143 1
survival of pheochromocytoma cell lines 0,0242 2
Free Radical Scavenging production of reactive oxygen species 0,0243 5
doi:10.1371/journal.pone.0008242.t003
Table 3. Cont.
Figure 3. Top ten signaling and metabolic pathways regulated by estradiol. For the functional categorization of genes, Fischer’s exact test
was used to calculate a p value (shown as bars) determining the probability that each biological function assigned to the network is due to chance
alone. The ratio (shown as squares) represents the number of differentially expressed genes in a given pathway divided by total number of genes that
make up that canonical pathway.
doi:10.1371/journal.pone.0008242.g003
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Cannonical pathway Significant genes included in each group of the top ten canonical pathways
Notch signaling FURIN, JAG2, NOTCH4, RFNG
Actin cytoskeleton signaling ACTN4, ARHGEF1, ARHGEF12,GRLF1, GSN, IQGAP3,MAPK3, MYH16, MYL9, PAK4, PDGFA, PIP5K1C, RAC2
Pentose phosphate pathway G6PD, GPI, PFKL, PGLS, PRPS2
Axonal guidance signaling ADAM15, AKT1, ARHGEF12, GNA11, GNB2, MAPK3, MYL9,PAK4, PDGFA, PLXNB2, PPP3CA, RAC2, SEMA6B
Integrin signaling ACTN4, AKT1, ARF3, ARF6, ITGA5, MAPK3, PAK4, PARVB, RAC2, RHOC, TNK2
Galactose metabolism GALT, UGALT, UGT2
VEGF signaling ARNT, PI3K, ACTC, BCL-XL
Huntington’s disease signaling AKT1, ARFIP2, CTSD, DCTN1, GNA11, GNB2, HDAC7A, POLR2L, SNCA, TGM2, UBE2S
N-glycan biosynthesis B4GALT5, DPM3, MAN1B1, MGAT4B
Inositol phosphate metabolism IP3K, PI4K, PI3K
doi:10.1371/journal.pone.0008242.t004
Figure 4. The most significant network regulated by estradiol is centered on TGFB1. Networks of genes were algorithmically generated
with the IPA software based on their connectivity and assigned a score. The intensity of the node color indicates the degree of up- (red) or down-
(green) regulation. A continuous line means a direct relationship between the two genes, whereas a discontinuous line indicates an indirect
association. The most significant network regulated by estradiol includes 33 genes with an assigned score of 62 and is centered on TGFB1.
doi:10.1371/journal.pone.0008242.g004
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Identification of Global Gene Expression Changes in
Estradiol–Treated HUVEC
The gene expression profile of human vascular cells treated with
or without estradiol was assessed by using the Human Genome
U133A plus 2.0 microarray technology from Affymetrix. A total of
1886 genes passed the ANOVA analysis, with fold changes
between 2.99 and 25.34. Table 2 (online supporting information)
summarizes most differentially expressed genes between control
and estradiol treated samples. Only genes with more than a 1.9-
fold change were included. As expected, the list of genes became
greater as a more permissive fold-change was selected. Only 4
genes (,14%) were up-regulated and 25 (,86%) were down-
regulated when the fold-change was higher than 2.5. By
decreasing the fold-change, the number of genes regulated by
estradiol increased, and there was a tendency to equate the
percentage of genes up-regulated and down-regulated. For
instance, with a fold-change higher than 1.9, 187 genes were
significantly regulated: 95 (,50%) were up-regulated and 92
(,50%) were down-regulated.
Comparison of Gene Expression Profiles by Hierarchical
Clusters and Principal Component Analysis (PCA)
Hierarchical Clusters were used to analyze the expression
profile of the different samples (Figure 1). Results identified broad
similarities among arrays hybridized with the mRNA of control
cells or among arrays hybridized with mRNA of cells treated with
estradiol. Even though the overall signal patterns found on the
mRNA hybridized arrays were similar, a small subset of regions
show differential expression signals between the mRNA of control
cells and mRNA of cells treated with estradiol.
PCA was applied to establish the interrelationships among the
samples used in our study. By visualizing projections of these
components in low-dimensional spaces, samples were grouped,
reflecting underlying patterns in their gene expression profiles.
Figure 2 depicts the PCA with the six pools clearly separated into
two sets, one set with three control samples, and the other set with
three estradiol-treated samples.
Functional Categorization of Genes
HUVEC genes regulated by estradiol were organized by function
to better understand their profile. This classification showed that
estradiol regulated a great number of genes mainly associated with
biological processes that include Cellular Growth and Proliferation;
Cell-to-cell Signaling; Cellular Assembly and Organization; Cellular
Compromise; Cellular Movement and Cell Death, as shown in
Table 3 (online supporting information). The Cardiovascular System
Development and Function also appears as one of the main
regulated. Genes with a role in Lipid and Carbohydrate Metabolism,
Cell Signaling, Endocrine System Disorders or Metabolic Disease
appear to be significantly regulated by estrogens as well. Among these
biological processes, the greater part of molecules induced by
estradiol in HUVEC is related to growth of cells (47 molecules), cell
death (47 molecules) and apoptosis (39 molecules), cell movement (32
molecules),growthofeukaryoticcells(25molecules)adhesioncells(22
molecules), colony formation (16 molecules), development of blood
vessels (15 molecules), cell surface receptor linked signal transduction
(14 molecules) and angiogenesis (10 molecules).
The functional characterization of data are presented in
Figure 3, which lists top ten canonical pathways regulated by
estrogen across both tissue types. The top five canonical pathways
based on their significance (P value) included Notch Signaling,
Actin Cytoskeleton Signaling, Pentose Phosphate Pathway, Axonal
Figure 5. QRT-PCR confirms some estradiol up-regulated selected genes from the microarray analysis. HUVEC were exposed to
different estradiol concentrations (0,01–100 nmol/L), and to 1 mmol/L ICI182780 alone or plus 1 nmol/L estradiol, and the relative expression of the
genes was quantified: (A) COX1, (B) DDAH2, (C) PLA2G4B, and (D) DHCR7. Data are percentage of control values and are mean 6 SEM of 5–19 values
(4–6 different experiments). * p,0.05, ** p,0.01 or *** p,0.001 vs. control cells, { p,0.05 vs. 0.01 nmol/L estradiol, and { p,0.05 vs. 1 nmol/L
estradiol.
doi:10.1371/journal.pone.0008242.g005
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each group of the top ten signaling pathways presented in Figure 3
are listed in Table 4.
When the IPA software was used to analyze the probe sets there
were 26 significant regulatory networks (score.2), of which 5 were
highly significant (score.20). The number one ranked network
(score=62, focus molecules=33) (Figure 4) is associated with
Cardiovascular System Development and Function, Cellular
Growth and Proliferation and Cell Morphology. Transforming
Growth Factor beta-1 (TGFB1) plays a central role in the
formation of this network. Top functions of the other four highly
significant networks are associated with Cellular Compromise,
Cellular Movement, Hematological System Development and
Function, Lipid Metabolism, Molecular Transport and Small
Molecule Biochemistry.
Microarray Analysis Verification
To validate the HUVEC gene expression changes induced by
estradiol in the microarray analysis, QRT-PCR was performed in
a separate series of follow-up studies of HUVEC exposed to
different concentrations (0,01–100 nmol/L) of estradiol. Target
genes were selected based upon their important cardiovascular
functions and were genes encoding for DDAH1, DDAH2,
PLA2G4A, PLA2G4B, COX1, COX2 and DHCR7.
Estradiol dose-dependent increased mRNA expression of
COX1, DDAH2, PLA2G4B, and DHCR7 (Figure 5). In all
cases, the effect afforded by 1 nmol/L estradiol was significantly
higher than that of 0,01 nmol/L estradiol. There were no
differences between the effects on gene expression induced by
the higher tested concentrations (1, 10 and 100 nmol/L), although
in the case of DHCR7 the effect of 10 nmol/L was 34% higher
than that of 1 nmol/l. The increased gene expressions induced by
1 nmol/L estradiol were similar to change levels obtained in the
microarray analysis (probeset 205128_x_at for COX1, - fold
change of 1.56 -p=0.007-, probeset 202262_x_at for DDAH2
-fold change: 1.37, p=0.045-, probeset 219095_at for PLA2G4B
-fold change 1.56, p=0.019-, and probeset 201790_s_at for
DHCR7 -fold change 1.79, p=0.005-).
The mRNA expression of COX2, DDAH1 and PLA2G4A
(Figure 6) remained unaltered under all the estradiol concentra-
tions, as in the microarray analysis (probeset 204748_at for COX2
-fold change: 21.18, p=0.541-, probeset 209094_at for DDAH1-
fold change: 21.03, p=0.743-, and probeset 210145_at for
PLA2G4A -fold change 21.06, p=0.570-).
Estradiol genomic effects are mainly mediated through ERa
and ERb. HUVEC express both types of ER (Figure 7), and no
changes in protein expression of both types of ER were observed
after exposure to estradiol, ICI 182780, or estradiol plus
ICI182780 (Figure 7). To study the role of ER on the effects
induced by estradiol on gene expression, cells were exposed to the
nonselective ER antagonist ICI182780. In cells exposed to
different concentrations (0,01 – 10 mmol/L) of ICI 182780 alone,
Figure 6. Unregulated genes in microarray analysis were also
unchanged by QRT-PCR. HUVEC were exposed to different estradiol
concentrations (0,01–100 nmol/L), and to 1 mmol/L ICI182780 alone or
plus 1 nmol/L estradiol, for 24 hours. Total cellular RNA was extracted,
and the relative expression of the genes was quantified using specific
primers for (A) COX2, (B) DDAH1 and (C) PLA2G4A. The GADPH gene
was used as control as described in Materials and Methods. Data are
expressed as percentage of control values and are mean 6 SEM of 5–17
values corresponding to 5 different experiments.
doi:10.1371/journal.pone.0008242.g006
Figure 7. Estrogen receptor alpha and beta protein expression
in HUVEC. Cells were exposed to 1 nmol/L estradiol with or without
1 mmol/L ICI182780 for 24 hours, and protein expression of (A) ERa and
(B) ERb were measured as stated in Materials and methods. A typical
immunoblotting image and relative levels assessed by densitometry of
bands of 66-kDa (ERa) or 56-kDa (ERb) are presented. Data are
percentage of control values and are mean 6 SEM of 6 values (3
different experiments).
doi:10.1371/journal.pone.0008242.g007
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(Table 5), thus discarding a direct effect of ICI 182780 on gene
profile. In cells coexposed to 1 nmol/L estradiol plus 1 mmol/L
ICI182780 for 24 h, estradiol-induced effects on gene expression
were completely abolished (Figure 5).
To further validate microarray data, COX1 and COX2 protein
expression were analyzed by immunoblotting (Figure 8A and 8B).
Estradiol increased COX1 protein expression up to 30 % of
control values, whereas COX2 protein expression remained
unchanged, in sharp agreement to data obtained from microarray
analysis and QRT-PCR assays. Moreover, estradiol-induced
COX1 up-regulation resulted in an increased production of
prostacyclin, the main vasodilatory prostanoid regulated by COX
activity (Figure 8C). These stimulatory effects of estradiol on
prostacyclin synthesis pathway were mediated through ER
activation, since were abolished in the presence of ICI 182780.
In a similar way, estradiol-induced changes in the DDAH gene
expression were correlated to similar changes in protein
expression. DDAH2 protein expression was increased in the
presence of estradiol, whereas DDAH1 remained unchanged
(Figure 9A and 9B). In vivo, DDAH degrades most of ADMA [20],
an endogenous inhibitor of NO synthase. The increased DDAH
expression resulted in decreased ADMA production (Figure 9C),
which in turn lead to an increased NO production after estradiol
exposure (Figure 9D). The effects of estradiol on the DDAH-
ADMA-NO pathways were mediated by ER, since were abolished
in the presence of ICI 182780.
Discussion
This study summarizes changes in complete gene expression in
human endothelial cells exposed to estradiol. We have identified
new genes that are up-regulated in endothelium by exposure to a
physiological concentration of estradiol (1 nmol/L) for 24 hours, a
time and a concentration selected according to previous work of
our group [19]. We have identified 1886 genes differentially
expressed. Taking advantage of ranked gene expression pathways,
results have shown that pathways related to cellular growth and
proliferation, cell-to-cell signaling and cellular organization,
movement and death were among the most differentially
expressed.
Canonical pathway analysis revealed Notch signaling as the
most significant signaling pathway modulated by estradiol.
Aberrant Notch signaling is implicated in carcinogenesis and
tumor angiogenesis [21], and interestingly with human pathologies
involving cardiovascular abnormalities [22]. Recently, it was
reported that Notch pathway regulates cell-cell or cell-matrix
interaction, contributing hence, to cell migration in situations of
tissue remodeling [23]. Also, Notch1 has been implicated in the
estradiol-induced increase in microvessel density in vivo and
therefore in estradiol-increased tumor angiogenesis in MCF7 cells
and HUVEC [24]. Our findings provide further support for the
important role that Notch signaling pathway plays on endothelial
effects of estradiol.
Estradiol has also important effects on other signaling pathways,
mainly in Actin Cytoskeleton Signaling, Integrin Signaling, and
Vascular Endothelial Growth Factor (VEGF) Signaling. These
pathways exert important vascular actions, such as maintaining
vascular integrity, regulating cell cycle, and promoting vasculo-
Table 5. Expression of selected genes from the microarray under different ICI 182780 concentrations.
ICI 182780 (mmol/L) Gene expresio ´n (% of control values)
DDAH-1 DDAH-2 PLA2G4A PLA2G4B COX-1 COX-2 DHCR7
0,01 96691 0 2 639 5 689 9 66 104611 99610 9864
0,1 110691 0 2 611 9567 10067 101679 6 691 0 2 67
19 5 681 0 8 612 10868 10667 10766 101691 0 5 610
10 101610 101671 0 5 612 106611 100639 8 616 10269
Data are expressed as percentage of control values and are mean6SEM of 4–7 values corresponding to 2 different experiments.
doi:10.1371/journal.pone.0008242.t005
Figure 8. Estradiol up-regulated COX1 protein expression
results in increased prostacyclin production through ER. HUVEC
were exposed to 1 nmol/L estradiol with or without 1 mmol/L
ICI182780, and protein expression of (A) COX1 and (B) COX2 and
prostacyclin production (C) were measured as stated in Materials and
methods. Data are percentage of control values and are mean 6 SEM of
6–8 values (3–4 different experiments). * p,0.05 or ** p,0.01 vs.
control cells, and { p,0.05 vs. estradiol-alone treated cells.
doi:10.1371/journal.pone.0008242.g008
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pathways significantly modulated by estradiol: Pentose Phosphate
Pathway, Galactose Metabolism, N-Glycan Biosynthesis and
Inositol Phosphate Metabolism. Some of these effects of estradiol
have already been described. Estradiol, for instance, has already
reported to increase HUVEC attachment to extracellular matrix
proteins, mainly up-regulating surface expression of b1, a5 and a6
integrins [25]. Estradiol directly regulates the glucose-6-phosphate
dehydrogenase (G6PDH) expression [26], the enzyme that directs
glucose carbons into the pentose phosphate pathway. Moreover,
estradiol-stimulated breast cancer cells have also increased pentose
phosphate pathway activity, suggesting that this pathway is
essential for estrogen-dependent cell proliferation [27]. Neverthe-
less, the majority of genes affected by estradiol treatment have
been described for the first time in our results and our data open
new approaches to discover unexplored estrogen-regulated
pathways and new vascular actions.
The IPA software outlined the most changed pathways in the
microarray data. Among them, TGFB1 plays a central role in the
formation of the number-one-ranked network, which contains 33
genes (Figure 4) and is associated with other important
cardiovascular networks, such as Cardiovascular System Devel-
opment and Function, Cellular Growth and Proliferation and Cell
Morphology. TGFB1 is a multifunctional peptide that controls
proliferation, differentiation, and other functions in many cell
types. In our study, TGFB1 was significantly up-regulated by
estradiol as a main effect, supporting its important role in
cardiovascular function. According to our results, estradiol exerts
an important role in vessel assembly and stabilization through
TGFB signaling pathways [28]. Moreover, TGFB pathway status
determines the antiatherogenic effect of estradiol in apoE-/-
hypercholesterolemic mice [29]. Furthermore, estradiol adminis-
tration to postmenopausal women increases circulating levels of
the active form of TGFB1 [30]. Altogether, these findings led to
the conclusion that TGFB1 is one of the main targets of estradiol
stimulation.
With the use of ICI 182780 in some experiments, our study
demonstrates that activation of ER by E2 modifies the expression
of several genes in HUVEC. In spite of some authors have found
that HUVEC do not express ERa [31], other investigators have
demonstrated the presence of both ERa and ERb mRNA in
HUVEC [32]. Data presented in Figure 7 demonstrate the
expression of both ERa and ERb protein in HUVEC, thus
confirming previous reports [33,34].
The extensive information gained from this first analysis has
resulted in the collection of new data and new genes that provide
other opportunities of study not explored so far, for example, the
increased expression of the DHCR7 gene when HUVEC were
exposed to different estradiol concentrations. This gene is
responsible for the last step in cholesterol synthesis, and its
inhibition results in hypocholesterolemia and accumulation of 7-
dehidrocholesterol [35], while different mutations of this gene
cause the Smith-Lemli-Opitz syndrome [36]. In our study,
DHCR7 expression induced by 1 nmol/L estradiol was com-
pletely abolished in the presence of ICI182780 (Figure 5D). This is
similar to the unique description of the relationship between this
gene and estradiol, in which the expression of DHCR7 on human
osteosarcoma cells was increased in response to estradiol through
receptor beta [37].
Other cardiovascular-relevant genes confirmed the consistency
of microarray data. Thus, the results are in accordance with
similar effects observed in endothelial cells, both measuring the
gene or the protein expression. COX are the rate-limiting step in
the formation of vasoactive prostanoids, such as prostacyclin and
thromboxane, from arachidonic acid [38]. Our results point to an
estradiol-induced, dose-dependent gene expression, resulting in
increased protein expression of COX-1 without effect on COX-2,
which in turn resulted in increased prostacyclin production. These
Figure 9. Estradiol up-regulated DDAH2 protein expression results in decreased ADMA production and increased NO release
mediated by ER. HUVEC were exposed to 1 nmol/L estradiol with or without 1 mmol/L ICI182780, and protein expression of (A) DDAH1 and (B)
DDAH2, along with (C) ADMA levels and NO production, were measured as stated in Materials and methods. Data are percentage of control values
and are mean 6 SEM of 9–12 values (4 different experiments). * p,0.05 or ** p,0.01 vs. control cells, and { p,0.05 vs. estradiol-alone treated cells.
doi:10.1371/journal.pone.0008242.g009
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some studies performed in ovine pulmonary artery endothelial
cells [39], but not in others [40]. Related to COX-mediated
prostanoid production, cytosolic phospholipase A2 activity is the
initial step which liberates arachidonic acid from the cell
membrane. In our study, PLA2G4B expression was reported to
be dose-dependent increased by estradiol, while the main subtype
PLA2G4A remained unaltered. Previous studies have reported an
increase in cytosolic phospholipase A2 protein expression, without
subtype differentiation, in ovine [41] and rat [42] uterine arteries
exposed to estradiol.
ADMA is an analogue of arginine, which is synthesized
endogenously and can act as inhibitor of nitric oxide synthase
[20]. Both DDAH are responsible in vivo for ADMA degradation
to citrulline and dimethylamine. According to the results obtained
in the microarray analysis and confirmed by QRT-PCR and
inmunoblotting, DDAH2 is increased in HUVEC exposed to
different concentrations of estradiol, whereas DDAH1 remains
unaltered. DDAH2, the main subtype in the cardiovascular
system, has already been reported to be increased by estradiol in
endothelium [19]. Moreover, the increased DDAH2 expression
resulted in decreased ADMA concentration and therefore,
increased NO release. Results of the present work further support
that increased DDAH2 expression is dependent on ER-dependent
genomic activity.
The strength of the current study is the careful design of the
experiments and the use of sample pools which contribute to
minimizing inter-individual variations. The average fold-change
induced by estradiol is relatively low, but it should be taken into
account that cells were exposed to estradiol concentrations that
were within physiological levels in premenopausal women [43].
Moreover, fold-changes and number of up-regulated genes in our
study were within the same range as that obtained in similar
studies performed with higher estradiol concentrations (10–
50 nmol/L) in different human breast cancer cell types [44].
Care should be taken determining clinically relevant conse-
quences. Much in vitro and in vivo experimental data support a
beneficial effect of estrogens on the cardiovascular system [6].
Observational studies have also consistently shown a benefit of
hormone replacement therapy on cardiovascular disease, but some
randomized studies have shown even some deleterious effects
[6,45]. New experimental approaches, such as the present study,
should contribute to conciliate the divergences observed between
clinical and experimental data.
In summary, our study generates a comprehensive estradiol-
mediated gene expression profile in HUVEC and characterizes in
detail the considerably different responses of control and estradiol-
treated endothelial cells. The present study provides the first
quantitative large-scale gene expression analysis of estradiol–
stimulated human vascular endothelial cells. Identification of
pathways regulated by estradiol may add to the knowledge base of
how estradiol contributes to a wide range of biological processes.
These results could lead to a deeper understanding of fundamental
insights of pathophysiological mechanisms involved in cardiovas-
cular diseases such as stroke or atherosclerosis at the level of gene
expression and provide a foundation for the development of better
therapeutic strategies for vascular disease.
Acknowledgments
The authors are indebted to Mrs. Rosa Aliaga, Mrs. Elvira Calap and Mr.
Carlos Bueno for their excellent technical assistance.
Author Contributions
Conceived and designed the experiments: AS CH. Performed the
experiments: AS MM ALF SN PJO CH. Analyzed the data: AS MM
SN PJO MAGP JJT CH. Contributed reagents/materials/analysis tools:
ALF MAGP JJT AC CH. Wrote the paper: AS MM SN JJT AC CH.
References
1. Mendelsohn ME, Karas RH (2005) Molecular and cellular basis of
cardiovascular gender differences. Science 308: 1583–1587.
2. Barrett-Connor E, Grady D (1998) Hormone replacement therapy, heart
disease, and other considerations. Annu Rev Pub Health 19: 55–72.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, et al. (1998) Randomized
trial of estrogen plus progestin for secondary prevention of coronary heart
disease in postmenopausal women. Heart and Estrogen/progestin Replacement
Study (HERS) Research Group. JAMA 280: 605–613.
4. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, et al. (2002)
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart
and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:
49–57.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al.
(2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal
women: principal results from the Women’s Health Initiative randomized
controlled trial. JAMA 288: 321–333.
6. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM (2006) Complex
Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and
Brain: Insights from Basic Science and Clinical Studies. Endocr Rev 27:
575–605.
7. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:
115–126.
8. Mendelsohn ME (2000) Mechanisms of estrogen action in the cardiovascular
system. J Steroid Biochem Mol Biol 74: 337–343.
9. Mendelsohn ME (2002) Protective effects of estrogen on the cardiovascular
system. Am J Cardiol 89: 12E–18E.
10. Trevino V, Falciani F, Barrera-Saldana HA (2007) DNA microarrays: a
powerful genomic tool for biomedical and clinical research. Mol Med 13:
527–541.
11. Archacki SR, Wang QK (2006) Microarray analysis of cardiovascular diseases.
Methods Mol Med 129: 1–13.
12. Hiltunen MO, Tuomisto TT, Niemi M, Bra ¨sen JH, Rissanen TT, et al. (2002)
Changes in gene expression in atherosclerotic plaques analyzed using DNA
array. Atherosclerosis 165: 23–32.
13. Graham D, McBride MW, Gaasenbeek M, Gilday K, Beattie E, et al. (2007)
Candidate genes that determine response to salt in the stroke-prone
spontaneously hypertensive rat: congenic analysis. Hypertension 50: 1134–1141.
14. Hermenegildo C, Oviedo PJ, Garcia-Perez MA, Tarin JJ, Cano A (2005) Effects
of phytoestrogens genistein and daidzein on prostacyclin production by human
endothelial cells. J Pharmacol Exp Ther 315: 722–728.
15. Li C, Hung Wong W (2001) Model-based analysis of oligonucleotide arrays:
model validation, design issues and standard error application. Genome Biology
2: research0032.
16. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI
gene expression and hybridization array data repository. Nucl Acids Res 30:
207–210.
17. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool
(REST(C)) for group-wise comparison and statistical analysis of relative
expression results in real-time PCR. Nucl Acids Res 30: e36.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement
with the Folin phenol reagent. J Biol Chem 196: 265–275.
19. Monsalve E, Oviedo PJ, Garcia-Perez MA, Tarin JJ, Cano A, et al. (2007)
Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine
production by cultured human endothelial cells. Cardiovasc Res 73: 66–72.
20. Vallance P, Leiper J (2004) Cardiovascular biology of the asymmetric
dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterios-
cler Thromb Vasc Biol 24: 1023–1030.
21. Leong KG, Karsan A (2006) Recent insights into the role of Notch signaling in
tumorigenesis. Blood 107: 2223–2233.
22. Uyttendaele H, Ho J, Rossant J, Kitajewski J (2001) Vascular patterning defects
associated with expression of activated Notch4 in embryonic endothelium.
PNAS 98: 5643–5648.
23. Lindner V, Booth C, Prudovsky I, Small D, Maciag T, et al. (2001) Members of
the Jagged/Notch gene families are expressed in injured arteries and regulate
cell phenotype via alterations in cell matrix and cell-cell interaction. Am J Pathol
159: 875–883.
24. Soares R, Balogh G, Guo S, Gartner F, Russo J, et al. (2004) Evidence for the
Notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol
18: 2333–2343.
Estradiol and Gene Expression
PLoS ONE | www.plosone.org 21 December 2009 | Volume 4 | Issue 12 | e824225. Cid M, Esparza J, Schnaper H, Juan M, Yague J, et al. (1999) Estradiol
enhances endothelial cell interactions with extracellular matrix proteins via an
increase in integrin expression and function. Angiogenesis 3: 271–280.
26. Thomas M, Bader C, Monet JD (1990) Sex steroid hormone modulation of
NADPH pathways in MCF-7 cells. Cancer Res 50: 1195–1200.
27. Forbes NS, Meadows AL, Clark DS, Blanch HW (2006) Estradiol stimulates the
biosynthetic pathways of breast cancer cells: Detection by metabolic flux
analysis. Metabolic Engineering 8: 639–652.
28. Soares R, Guo S, Ga ¨rtner F, Schmitt F, Russo J (2003) 17b-Estradiol-mediated
vessel assembly and stabilization in tumor angiogenesis requires TGFb and
EGFR crosstalk. Angiogenesis 6: 271–281.
29. Gourdy P, Schambourg A, Filipe C, Douin-Echinard V, Garmy-Susini B, et al.
(2007) Transforming growth factor activity is a key determinant for the effect of
estradiol on fatty streak deposit in hypercholesterolemic mice. Arterioscler
Thromb Vasc Biol 27: 2214–2221.
30. Djurovic S, Os I, Hofstad AE, Abdelnoor M, Westheim A, et al. (2000)
Increased plasma concentrations of TGF-beta1 after hormone replacement
therapy. J Int Med 247: 279–285.
31. Toth B, Scholz C, Saadat G, Geller A, Schulze S, et al. (2008) Estrogen receptor
modulators and estrogen receptor beta immunolabelling in human umbilical
vein endothelial cells. Acta Histochemica;doi:10.1016/j.acthis.2008.05.006.
32. Wagner AH, Schroeter MR, Hecker M (2001) 17beta-estradiol inhibition of
NADPH oxidase expression in human endothelial cells. FASEB J 15:
2121–2130.
33. Oviedo PJ, Hermenegildo C, Tarin JJ, Cano A (2007) Raloxifene increases
proliferation of human endothelial cells in association with increased gene
expression of cyclins A and B1. Fertil Steril 88: 326–332.
34. Harris HA (2007) Estrogen Receptor-{beta}: Recent Lessons from in Vivo
Studies. Mol Endocrinol 21: 1–13.
35. Kolf-Clauw M, Chevy F, Wolf C, Siliart B, Citadelle D, et al. (1996) Inhibition
of 7-dehydrocholesterol reductase by the teratogen AY9944: a rat model for
Smith-Lemli-Opitz syndrome. Teratology 54: 115–125.
36. Witsch-Baumgartner M, Loffler J, Utermann G (2001) Mutations in the human
DHCR7 gene. Hum Mutat 17: 172–182.
37. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, et al. (2005)
Estrogen Receptor {alpha} and {beta} Heterodimers Exert Unique Effects on
Estrogen- and Tamoxifen-Dependent Gene Expression in Human U2OS
Osteosarcoma Cells. Mol Endocrinol 19: 1555–1568.
38. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural,
cellular, and molecular biology. Annu Rev Biochem 69: 145–182.
39. Jun SS, Chen Z, Pace MC, Shaul PW (1998) Estrogen upregulates
cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium.
J Clin Invest 102: 176–183.
40. Hermenegildo C, Oviedo PJ, Cano A (2006) Cyclooxygenases regulation by
estradiol on endothelium. Curr Pharm Des 12: 205–215.
41. Rupnow HL, Phernetton TM, Modrick ML, Wiltbank MC, Bird IM, et al.
(2002) Endothelial vasodilator production by uterine and systemic arteries. VIII.
Estrogen and progesterone effects on cPLA2, COX-1, and PGIS protein
expression. Biol Reprod 66: 468–474.
42. Farina MG, Billi S, Leguizamon G, Weissmann C, Guadagnoli T, et al. (2007)
Secretory and cytosolic phospholipase A2 activities and expression are regulated
by oxytocin and estradiol during labor. Reproduction 134: 355–364.
43. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Cano A (2002) Estradiol
reduces F2alpha -isoprostane production in cultured human endothelial cells.
Am J Physiol Heart Circ Physiol 283: H2644–H2649.
44. Cicatiello L, Scafoglio C, Altucci L, Cancemi M, Natoli G, et al. (2004) A
genomic view of estrogen actions in human breast cancer cells by expression
profiling of the hormone-responsive transcriptome. J Mol Endocrinol 32:
719–775.
45. Stevenson JC (2007) HRT and the primary prevention of cardiovascular disease.
Maturitas 57: 31–34.
Estradiol and Gene Expression
PLoS ONE | www.plosone.org 22 December 2009 | Volume 4 | Issue 12 | e8242